Solving Drug Delivery’s Toughest Challenges – From Lab to Life.
Likarda partners with leading biotech, pharma, and research organizations as a trusted formulation and drug delivery partner. We provide enabling technologies for small molecules, biologics and cell therapies using our proprietary Core-Shell Spherification® (CSS®) encapsulation platform.
Core-Shell Spherification®
Our patented CSS® encapsulation technology surrounds cells or drugs in protective hydrogel shells, allowing for sustained delivery and better outcomes—no matter the challenge.
The platform is fully customizable, enabling precise control over release timing, bead size, and therapeutic payload for a wide range of applications.
Likarda is investing in new manufacturing capabilities to meet the growing demand for our hydrogel delivery platforms. In 2025, we will introduce proprietary CSS® equipment, empowering partners with scalable encapsulation solutions for biologics, cells, and small molecules.
Combine (Hydrogel Precursor + API)
Microparticle Formation
Crosslink Hydrogel
Rinse Process
Quality ControlPowering the Future of Medicine
Likarda is a proven partner to biotech and pharmaceutical companies, delivering revenue-generating solutions today through our advanced hydrogel platforms and drug delivery technologies.
Cell Therapies
Learn more about Cell Therapy SolutionsCell-based encapsulation systems designed to protect, deliver, and sustain the function of living cells at the target site.
Cryopreservation & Logistics
Discover Next-Gen Cryopreservation & LogisticsSolutions that protect therapeutic cells and compounds during storage and transport—eliminating the need for liquid nitrogen and reducing environmental impact.
Large & Small Molecules
Explore Delivery Solutions for Large & Small MoleculesCustom hydrogel platforms that enable controlled, extended release and delivery of biologics and small molecule drugs.
Built to Solve the Toughest Therapeutic Challenges
Unlike traditional cell therapies where delivered cell quantities can vary widely, Likarda leverages AI-powered cell quantification to ensure precise, reproducible dosing—leading to more predictable and effective therapeutic outcomes.
Contact us to find out how we can help.
Success StoriesPowered by Likarda
Antibodies (NovoSphere™)
Monthly mAb dosing achieved through lyophilized, extended-release formulation.
Osteoarthritis Therapy (ViscoCell™)
Achieving 4x extended release in preclinical models.
Diabetes Treatment (EnduraCell™)
Sustained blood glucose control without daily insulin injections in preclinical models.
Cryopreservation (LiberaCell™)
Liver spheroids maintained >80% viability and function post-thaw.
Liver Disease (EnduraCell™)
30-day functional liver spheroids outperforming alginate models.
CAR-T Cells (VitaCell™)
Cryopreserved cells delivered with 95% viability post-thaw.
Cryopreservation (AegisCell™)
Enabled safe, effective T-cell cryopreservation and shipment for up to two weeks on dry ice.
Extending the Life of Fresh Cells (LiberaCell™)
LiberaCell™ creates a supportive environment that maintains cell viability and metabolic activity without the need for media exchanges or ultra-cold conditions.
